Life Time Inc., a “health and wellness pioneer,” has more than 170 athletic country clubs across the U.S. The chain of clubs also extends into Canada.
In a post on LinkedIn, Dexcom said it announced the new partnership at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Through the partnership, the Dexcom Stelo system becomes the “Official Glucose Biosensor of Life Time.”
Stelo, the U.S.’s first glucose biosensor available without a prescription, is available for purchase at Stelo.com. The company expects to offer the device through the Life Time app soon as well.
Dexcom became the first company to receive FDA clearance for an OTC CGM when the FDA cleared Stelo in March 2024. The company began its official rollout of Stelo in August. Abbott followed in June with FDA clearance for its over-the-counter Libre Rio.
Dexcom designed Stelo, a small, wearable sensor, specifically for people with type 2 diabetes who do not use insulin. Worn on the back of the arm, the sensor provides insights directly to a user’s smartphone. Stelo features a 15-day wear based on the G7 platform. It offers a software experience tailored specifically for non-insulin users. The company said it makes it easier for the target population to access CGM and offers an option for those who don’t have insurance coverage for CGM.
In addition to availability through Life Time, Dexcom expects promotions, events, and activations that highlight the critical role glucose insights play in achieving overall health goals. The company aims to help more people take care of their health through glucose biosensing technology.
“We look forward to seeing this partnership come to life in 2025,” Dexcom said on LinkedIn.
